Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 30;13(5):1098.
doi: 10.3390/biomedicines13051098.

Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure

Michalina Mazurkiewicz  1 , Patryk Bodnar  2 , Dominika Blachut  1 , Tomasz Chwalba  1 , Wiktor Wagner  3 , Eliza Barczyk  3 , Ewa Romuk  4 , Wojciech Jacheć  1 , Celina Wojciechowska  1
Affiliations
Review

Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure

Michalina Mazurkiewicz et al. Biomedicines. .

Abstract

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have become integral in treating both diabetes mellitus and heart failure, independent of left ventricular ejection fraction. Their pleiotropic effect influences multiple mechanisms, enhancing the function of various systems within the body. They exhibit nephroprotective and cardioprotective effects by improving cell metabolism, endothelial function, and slowing the fibrosis of the cardiac muscle, and they also have a beneficial impact on other organs. At the cellular level, they protect against the harmful effects of free radicals both by lowering glucose levels and by supporting the function of the antioxidant system. Moreover, SGLT-2 inhibitors can modify the metabolism of adipocytes by affecting the production of cytokines such as adiponectin-which increases insulin sensitivity, leading to weight loss and improved glycemic control.

Keywords: SGLT-2 inhibitors; adipokines; adiponectin; adipose tissue; flozins; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of adipocytes: (a) white, (b) brown.
Figure 2
Figure 2
Effects of adipokines on different organs and systems.
Figure 3
Figure 3
Schematic diagram of the interaction of adiponectin and insulin signaling pathways. (The arrows highlight the functional interplay between insulin and adiponectin signaling pathways).
Figure 4
Figure 4
Tissue-specific function of adiponectin. (↑—increase, ↓—reduce).
Figure 5
Figure 5
Effects of SGLT-2 inhibitors on adipose tissue.
See this image and copyright information in PMC

References

    1. Waki H., Tontonoz P. Endocrine functions of adipose tissue. Annu. Rev. Pathol. 2007;2:31–56. doi: 10.1146/annurev.pathol.2.010506.091859. - DOI - PubMed
    1. Gregoire F.M., Smas C.M., Sul H.S. Understanding adipocyte differentiation. Physiol. Rev. 1998;78:783–809. doi: 10.1152/physrev.1998.78.3.783. - DOI - PubMed
    1. Song T., Kuang S. Adipocyte dedifferentiation in health and diseases. Clin. Sci. 2019;133:2107. doi: 10.1042/CS20190128. - DOI - PMC - PubMed
    1. Rosenwald M., Wolfrum C. The origin and definition of brite versus white and classical brown adipocytes. Adipocyte. 2014;3:4–9. doi: 10.4161/adip.26232. - DOI - PMC - PubMed
    1. Petersen M.C., Shulman G.I. Mechanisms of Insulin Action and Insulin Resistance. Physiol. Rev. 2018;98:2133–2223. doi: 10.1152/physrev.00063.2017. - DOI - PMC - PubMed

LinkOut - more resources